Scara5 and osteoporosis in type 2 diabetes mellitus - Version 5.13
Research type
Research Study
Full title
Investigation of Scara5 expression in subjects diagnosed with osteoporosis and diabetes.
IRAS ID
274037
Contact name
Nicole Horwood
Contact email
Sponsor organisation
University of East Anglia
Clinicaltrials.gov Identifier
Not applicable, Not Applicable
Duration of Study in the UK
1 years, 11 months, 29 days
Research summary
Osteoporosis is a condition where bones lose strength, making a person more likely to break a bone than the average adult. In the UK over 3 million people have osteoporosis leading to over 300,000 fragility fractures per year. Osteoporosis and broken bones have a number of known causes, which can reduce the bone mass or affect the bones’ strength, including diet, smoking, ageing, genetic predisposition, autoimmune disorders and diabetes (1, 2).
There is an inverse correlation between bone mass and bone marrow adipose tissue (BMAT), which has been reported in human studies particularly in skeletal ageing and osteoporosis, where high marrow adiposity is closely linked to reduced bone integrity and increased fracture risk. BMAT and bone forming osteoblasts arise from the same precursor in the bone marrow, mesenchymal stromal cells (MSCs). The scavenger receptor class A member 5 (Scara5) resulted involved in the differentiation of MSCs into adipocytes instead of osteoblasts (H. Lee et al, 2015) and this could affect the bone integrity negatively thus increasing the fracture risks.
This study aims to test the association of Scara5 with bone mineral density and type 2 diabetes mellitus.REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
20/NW/0160
Date of REC Opinion
21 Apr 2020
REC opinion
Further Information Favourable Opinion